Articles On Race Oncology (ASX:RAC)

The Race Oncology Ltd (ASX: RAC) share price is having a very strong session. In morning trade, the ASX All Ords share is up an impressive 12% to 86 cents. Why is this ASX All Ords share rising? Investors have been buying the oncology comp...

Race Oncology (ASX:RAC) has announced that Laurus Labs (has successfully produced its first batch of bisantrene dihydrochloride.

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Race Oncology (ASX:RAC) produces its first batch of bisantrene dihydrochloride under cGMP standards with its partner Laurus Labs This achievement paves the way for Race’s flagship drug RC220 RAC’s next steps include transferring the c...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Race Oncology (RAC) has shown once again that a combination of bisantrene with other chemodrugs leads to a more successful cancer plan for patients A wide range of human cancer cell lines were tested with combined dosages with 113 of 14...

The market may be falling for a fourth day in a row, but that hasn't stopped a couple of ASX healthcare shares from charging higher today. Here's what is getting investors excited about them on Wednesday: Race Oncology Ltd (ASX: RAC) The...

According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. W...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

The S&P ASX 200 was down 0.73% in August with mid caps and small caps down 1.3% for the month Eight of 11 sectors down in August with consumer discretionary leading winners and utilities the laggards Tech stock 4DS Memory rises more th...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Race Oncology (RAC) announces that Dr Peter Smith assumes the role of Executive Director following Damian Clarke-Bruce’s resignation as CEO Dr John Cullity is retiring from his Non-Executive Director role Dr Daniel Tillett joins as a...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

MoneyTalks is Stockhead’s regular recap of the ASX stocks, sectors and trends that fund managers and analysts are looking at right now. Today we hear from Andrew Chapman, managing director of Merchant Group Australia.   What sector is hot r...

ASX benchmark falls 0.86% for the day, dragged down by bad news from China. Telcos, Energy and InfoTech tried their best, but the overall gloom was too much to fight. Lithium Universe (ASX:LU7) banks a solid market debut as it kicks off i...

Race Oncolocy’s new corporate strategy has been designed to maximise the inherent value of its core asset bisantrene RC220 for both its cancer-fighting and cardio-protective properties. Clinical stage global biotech Race Oncology (ASX:RAC)...

Recce Pharma surges 20pc on anecdotal results Emyria launches a ketamine-assisted therapy (KAT) program Race Oncology unveils new corporate strategy   Recce surges on anecdotal results Recce Pharma (ASX:RCE) raced higher by more than 20%...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Race Oncology (RAC) receives an additional $1.66 million in an R&D Tax Incentive Refund from the ATO for FY22 The refund relates to successful R&D activities conducted in overseas jurisdictions during the financial year RAC M...

Race Oncology executes agreement with leading global contract development and manufacturing organisation, Ardena as additional partner for GMP manufacturing of flagship RC220 bistanrene formulation Ardena has a long track record of providi...

Race Oncology (RAC) partners with Ardena to bolster the manufacturing capabilities of its flagship intravenous (IV) formulation of bisantrene, RC220 The collaboration serves as a primary source for EU-compliant supplies of RC220 in Euro...

Race executes worldwide license agreement with City of Hope, one of the largest cancer research and treatment organisations in the United States. Under the agreement, Race will exclusively secure rights to a City of Hope patent application...

Race executes worldwide license agreement with City of Hope, one of the largest cancer research and treatment organisations in the United States. Under the agreement, Race will exclusively secure rights to a City of Hope patent application...

Bod Science provided a ‘landmark update’ on its Phase IIB insomnia clinical trial Neurotech received an ethics approval to begin Phase I/II clinical trial Incannex intends to list all its shares on the Nasdaq   Bod Science provides ‘landm...

The ASX is expected to kick off the week on a positive after last week’s tumble on Wall Street, which left stocks lower at closing after the US June jobs report strengthened possibilities for a rate rise. Important news to watch out for...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Orphan diseases are those impacting less than 200,000 patients Orphan drug designation ensures an exclusivity period for pharma companies The average orphan drug in the US retails for US$7,000 per month   Rare or ‘Orphan’ diseases affect...

I’m about to tell you about some excellent All Ordinaries (ASX: XAO), or All Ords, ASX shares that I think are very cheap. Certainly, there’s been plenty of volatility in recent times, but this gives us an opportunity to buy shares at...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

If you’re looking to take advantage of recent weakness in the lithium industry to make some investments, then you might want to check out the three buy-rated ASX 200 lithium shares listed below. Here’s what analysts are saying about th...

A key part of the Australian economy is the mining sector. In light of this, it will come as little surprise to learn that there are a large number of mining shares listed on the ASX. But given the vast options it can be hard to decide whi...

The S&P/ASX 200 Index (ASX: XJO) ended the week on a high, rising 0.51% to finish the session at 7,361.6 points – its highest close since early March. That also leaves it 1.98% higher week-on-week. It followed a strong session over o...

S&P/ASX 200 Index (ASX: XJO) gold shares are enjoying some healthy tailwinds from a fast-rising gold price. So far in 2023, the S&P/ASX All Ordinaries Gold Index (ASX: XGD), which also contains some smaller gold stocks outside of...

The materials sector has recovered to make a slight gain this morning, as the impact of the now-category-three cyclone Ilsa in Port Hedland and the Pilbara region appears to be lower than expected. WA1 Resources (WA1) has put its drillin...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a positive note. At the time of writing, the benchmark index is up 0.4% to 7,351.1 points. Four ASX shares that are climbing more than most today are...

Race Oncology (RAC) flags the multi-billion-dollar market potential of its Zantrene drug as a potential cardio-protective agent and an anti-cancer agent The company says an independent analysis suggests a use case in nearly its entire t...

The IGO Ltd (ASX: IGO) share price is besting the benchmark S&P/ASX 200 Index (ASX: XJO) on Friday. It comes as the green metals miner reveals its secured land to build its proposed Integrated Battery Material Facility (IBM Facility)....

S&P/ASX 200 Index (ASX: XJO) gold shares are charging higher today. In morning trade on Wednesday, the ASX 200 is up 0.2%. Not bad. But well behind the 3.3% gain posted by the S&P/ASX All Ordinaries Gold Index (ASX: XGD), which als...

The S&P/ASX 200 Index (ASX: XJO) lifted higher on Tuesday, rising 0.18% to close at 7,236 points. Its gains came as the Reserve Bank of Australia (RBA) put a pause on rate hikes this afternoon, leaving the cash rate at 3.6%. It comes a...

It’s starting to feel like a while since the beaten-up ASX share BWX Ltd (ASX: BWX) has been available for trading on the ASX. That’s because it has been. BWX shares last traded on the share market back on 23 March, almost two weeks ago. B...

The S&P/ASX 200 Index (ASX: XJO) is having a subdued session ahead of the RBA meeting. In afternoon trade, the benchmark index is a few points lower at 7,220.1 points. Four ASX shares that are not letting that hold them back are list...

The All Ordinaries Index (ASX: XAO) is in the red today – just. The benchmark is down 0.07% right now at 7,411.3. And that performance is being smashed by four ASX All Ords shares, each with big news. Let’s take a closer look at the upda...

Paradigm Biopharma demonstrates efficacy of knee osteoarthritis drug Race Oncology released a third-party report showing the potential for Zantrene Emyria and Aspen Australia have signed an exclusive binding deal   Paradigm Biopharmaceuti...

Race Oncology (ASX:RAC) has updated investors with market research commissioned to better understand the commercial potential for its lead asset, Zantrene, as a cardio-protective and anti-cancer agent in settings where anthracycline...

Benchmark set to finish close to flat as Energy stocks slump again Goldies are surging again, with that sector up 1.3% for the day Even the big banks are bracing for trouble with talk of a crisis getting louder by the day   After a modera...

With so many shares to choose from on the ASX, it can be hard to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares that leading brokers have named as b...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a small gain. At the time of writing, the benchmark index is up 0.25% to 6,973.6 points. Four ASX shares that are climbing more than most today...

Another week, another bank collapse? Hopefully not this week… we’ve had enough of those, thank you very much. The RBA’s next rates call gets tougher And it seems the US Federal Reserve and the Bank of England (among others) are suita...